• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Argenx Se ADR (NQ: ARGX )

    595.58 +9.28 (+1.58%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Argenx Se ADR

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'
    Argenx SE ADR shares jumped after impressive earnings. Analysts raised price targets and noted strong pipeline and global expansion. 
    Via Benzinga
    This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
    Via Benzinga
    This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
    Via Benzinga
    The Latest Analyst Ratings For argenx
    Via Benzinga
    Biotech Stocks : Are You A Trader Or A Longer Term Investor?
    Biotech bull market is intact as indicated by large cap biopharma and the best performing funds. 
    Via Talk Markets
    Peeling Back The Layers: Exploring argenx Through Analyst Insights
    Via Benzinga
    What 25 Analyst Ratings Have To Say About argenx
    Via Benzinga
    The Analyst Verdict: argenx In The Eyes Of 27 Experts
    Via Benzinga
    Breaking Down argenx: 12 Analysts Share Their Views
    Via Benzinga
    Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
    Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
    Via Investor's Business Daily
    Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
    Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... 
    Via Benzinga
    Exposures Product Safety
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    The Analyst Verdict: argenx In The Eyes Of 12 Experts
    Via Benzinga
    Key Takeaways From argenx Analyst Ratings
    Via Benzinga
    This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
    Via Benzinga
    Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
    The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030. 
    Via Benzinga
    Exposures Product Safety
    Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
    This is the second approval for the biotech company's drug, Vyvgart Hytrulo. 
    Via Investor's Business Daily
    Exposures Product Safety
    Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
    Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
    Via Investor's Business Daily
    Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
    Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
    Via Benzinga
    Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
    The company says it's still running additional testing of the drug, calling the results "positive." 
    Via Investor's Business Daily
    Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024
    ARGX stock results show that argenx missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
    Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current... 
    Via Benzinga
    Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.